Merck Secures Global License for LaNova's LM-299 PD-1/VEGF Antibody in $588 Million Deal

MT Newswires Live11-14

Merck (MRK) said Thursday it has acquired an exclusive global license from LaNova Medicines to develop, manufacture, and commercialize LM-299, an investigational PD-1/VEGF bispecific antibody.

As part of the deal, LaNova will receive a $588 million upfront payment and may earn up to $2.7 billion in milestone payments for development, regulatory, and commercial achievements across various indications, Merck said.

The deal is expected to close in Q4, subject to Hart-Scott-Rodino Act clearance and other conditions, Merck added.

Merck stock was up 0.4% in recent premarket activity.

Price: 98.91, Change: +0.41, Percent Change: +0.42

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment